Anti-P110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement

Flavia Scuderi, Mariapaola Marino, Lucrezia Colonna, Francesca Mannella, Amelia Evoli Stampanoni-B, Carlo Provenzano, Emanuela Bartoccioni*

*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivistaArticolo in rivista

94 Citazioni (Scopus)


Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness and pathogenetic autoantibodies directed against the nicotinic acetylcholine receptor (seropositive myasthenia gravis; SPMG). Nearly 15% to 20% of MG patients do not have these antibodies (seronegative myasthenia gravis; SNMG), but several evidence indicate that these patients have circulating pathogenic autoantibodies directed against other muscle antigens. Using the TE671 rhabdomyosarcoma cell line as an antigen source, we analyzed sera from 63 SNMG and 26 SPMG patients and 26 healthy blood donors by FACS analysis. We found that 40 of 63 SNMG patients and only 1 of 26 SPMG patients had IgG binding to the TE671 cell line. None of the sera bound to the unrelated MRC5 cell line. To identify the antigen, we analyzed sera immunoreactivity in more detail by immunoprecipitation of biotinylated membrane proteins from TE671 cells. When the immunoprecipitated proteins were separated by SDS-PAGE electrophoresis and then transferred to nitrocellulose membranes, we found that SNMG IgG identify a band corresponding to a protein with a molecular weight of 110 kDa (P110), which is not recognized by seropositive MG sera. This anti-P110 immunoreactivity is significantly associated with a distinct clinical picture characterized by a prominent involvement of ocular and bulbar muscles, with frequent respiratory problems (p < 0.005), and is recognized by a specific antimuscle specific kinase (MUSK) antiserum. In a recent article, the presence of anti-MuSK antibodies was described in SNMG. Our results confirm the presence of these antibodies in SNMG and suggest that anti-Pl10/MuSK autoantibodies identify a subtype of SNMG in which the different pathogenesis induces the distinct clinical picture.
Lingua originaleEnglish
pagine (da-a)1139-1146
Numero di pagine8
RivistaLaboratory Investigation
Stato di pubblicazionePubblicato - 2002


  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Autoantibodies
  • Child
  • Eye Diseases
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myasthenia Gravis
  • Oculomotor Muscles
  • Receptors, Cholinergic
  • Rhabdomyosarcoma
  • Tumor Cells, Cultured


Entra nei temi di ricerca di 'Anti-P110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement'. Insieme formano una fingerprint unica.

Cita questo